HLSE:ORNBVPharmaceuticals
Orion Oyj Cancer Trial Adds Potential Upside To Discounted Share Price
Orion Oyj has started a Phase 1b/2 basket trial of ODM-212, an oral pan TEAD inhibitor.
The study targets patients with advanced cancers, including mesothelioma, KRAS G12C mutated non small cell lung cancer, and pancreatic cancer.
The trial initiation marks a new clinical step for Orion Oyj in oncology research.
For investors watching HLSE:ORNBV, this new trial adds a fresh clinical asset to an already established pharma business. The share price is currently €68.7, with the stock up 3.1%...